1,720,998 research outputs found
Nickel-specific CD8+ and CD4+ T cells display distinct migratory response to chemokines produced during allergic contact dermatitis.
No full text
CD56brightCD16(-) NK cells accumulate in psoriatic skin in response to CXCL10 and CCL5 and exacerbate skin inflammation.
No full textHuman CD4+ T lymphocytes with remarkable regulatory functions on dendritic cells and nickel-specific Th1 immune responses.
No full textInterleukin 17 is produced by both Th1 and Th2 lymphocytes, and modulates interferon-g- and interleukin 4-induced activation of human keratinocytes.
No full textHuman CD25+ regulatory T cells maintain immune tolerance to nickel in healthy, non allergic individuals.
No full textAnti-TNF-a chimeric antibody (Infliximab) inhibits activation of psoriatic CD4+ and CD8+ T lymphocytes and impairs dendritic cell functions
No full textEfficacy of oral hyposensitization in allergic contact dermatitis caused by nickel
Full text linkBackground. Nickel contact allergy remains common in Western countries, and the dermatitis may require prolonged treatment. The development of new strategies aimed at improving the quality of life of affected individuals is needed. Objectives. To investigate the efficacy of oral hyposensitization in nickel-allergic individuals and how this affects in vitro T cell responsiveness to the metal. Methods. Twenty-eight nickel-allergic patients received a daily dose of 50 μg of elemental nickel (given as NiSO 4·6H 2O) in cellulose capsules for 3 months. Severity of clinical manifestations, in vivo nickel responsiveness and in vitro T cell responses to the metal were assessed after 1 and 3 months. Results. Twenty-six patients finished the study. In these patients, oral hyposensitization ameliorated clinical manifestations despite continued nickel exposures, and increased the threshold of skin responsiveness to nickel. The 12 enrolled patients in the immunological study showed decreased in vitro T lymphocyte responsiveness to the metal, in terms of both cell proliferation and cytokine release. In the 1-year follow-up, 50% of the patients experienced relapses of the clinical manifestations at sites of topical exposure to nickel. Conclusions. Our study suggested therapeutic efficacy of oral hyposensitization in allergic individuals. Placebo-controlled studies are required to confirm the results and determine the optimal therapeutic regimen for prolonged beneficial effects
- …
